<DOC>
	<DOCNO>NCT01159080</DOCNO>
	<brief_summary>To clarify tacrolimus-sparing regimen minimal tacrolimus dose together mycophenolate sodium dose increment preserve renal allograft function without rise adverse effect Primary endpoint : 1. estimate GFR ( MDRD equation ) 12 month randomization 2. estimate GFR change randomization end study ( calculate MDRD equation Nankivell equation )</brief_summary>
	<brief_title>Treatment optImuM Dose calcineUrin Inhibitor Mycophenolate Sodium Kidney Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>&lt; Inclusion criterion &gt; 1 . The patient age 20 75 year receive kidney transplantation one five year prior study . 2 . Taking tacrolimus corticosteroid , without additional purine synthesis inhibitor within recent 3 month 3 . Patients serum creatinine ( sCr ) level ≤ 2.0 mg/dL variation sCr &lt; 30 % recent 3 month 4 . Patients urine proteinuria/creatinine ratio ( PCR ) ≤ 1 g/g , 24 hour urine protein ≤ 1g/day recent 3 month 5 . Patients provide informed consent . &lt; Exclusion criterion &gt; 1 . Patients receive combined nonrenal transplantation , multiple kidney transplantation retransplantation 2 . Patients whose graft nonheart beat cadaveric donor 3. graft HLAidentical living relate donor 4 . ABO blood group incompatible donor HLA desensitize recipient 5 . Patients hypersensitivity history mycophenolate sodium , mycophenolate acid , mycophenolate mofetil , excipients 6 . Patients hypoxanthin eguanine phosphoribosyltransferase LeschNyhan syndrome KelleySeegmiller syndrome 7 . Patients history disease could affect absorption study medication ( e.g . diabetic gastropathy , previous gastrectomy ) 8 . Patients positive serologic test result , recipient donor , human immunodeficiency virus , hepatitis B C virus 9 . Patients liver function test abnormality ( alanine aminotransferase , aspartate aminotransferase , total bilirubin &gt; 3 time upper normal limit ) , neutropenia ( absolute neutrophil count &lt; 1,500/uL white blood cell count &lt; 2,500/uL ) , thrombocytopenia ( platelet &lt; 75,000 ) 10 . Patients history cancer within 5 year , except successfully treat localize nonmelanocytic skin cancer 11 . Patients either pregnant , lactating , plan become pregnant next 12 month 12 . Patients take medicine trial within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>immunosuppression control kidney transplantation</keyword>
</DOC>